Research progress of pathogenic relationship between triglycerides and coronary heart disease
-
摘要: 大量的临床和流行病学研究已经证实了高胆固醇血症 (尤其是低密度脂蛋白胆固醇) 是冠心病发病的一个独立危险因素, 调脂治疗可以显著降低冠心病的死亡率和患病率。然而, 血浆三酰甘油 (TG) 对冠心病的致病作用还不甚明确。本文就目前TG与冠心病发病关系的一些研究热点作一综述, 以对冠心病患者高TG血症的治疗提供帮助。Abstract: Many clinical and epidemiological studies have certified that hyperlipoidemia (especially the low density lipoprotein cholesterol) is an independent risk factor of coronary heart disease (CHD), and lipid lowering therapy could reduce mortality and morbidity of cardiovascular disease significantly.However, the relation between plasma triglyceride and cardiovascular disease is still uncertain.We made a review about the relation of triglyceride and CHD, in order to supply some suggestions on the treatment of hypertriglyceridemia in CHD patients.
-
Key words:
- triglyceride /
- coronary heart disease /
- risk factor /
- pathogenic relationship
-
-
[1] JOHANSEN C T, KATHIRESAN S, HEGELE R A.Genetic determinants of plasma triglycerides[J].J Lipid Res, 2011, 52:189-206.
[2] BLOM D.Hypertriglyceridemia:aetiology, Complication and management:review article[J].JEMDSA, 2010, 15:11-17.
[3] CLAUDIO P O, LIVIA P, GIOVANNI L V, et al.Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia[J].JAMA, 2005, 33:410-417.
[4] SCHAAP F G, RENSEN P N, VOSHOL P J, et al.ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis[J].J Biol Chem, 2004, 279:27941-27947.
[5] SHIMADA M, ISHIBASHI S, GOTODA T, et al.Over expression of human lipoprotein lipase protects diabetic transgenic mice from diabetic hypertriglyceridemia and hypercholesterolemia[J].Arterioscler Thromb Vasc Biol, 1995, 15:1688-1694.
[6] WEINSTOCK P H, BISGAIER C L, AALTOSETALA K, et al.Severe hypertriglyceridemia, reduced high density lipoprotein and neonatal death in lipoprotein lipase knockout mice[J].J Clin Invest, 1995, 96:2555-2568.
[7] SOZIO M, CRABB D W.Alcohol and lipid metabolism[J].Am J Physiol Endocrinol Metab, 2008, 295:E10-E16.
[8] OGUNRO P S, OLOGUNAGBA P O.Plasma level of atherogenic and anti-atherogenic factors among palm wine drinkers of rural southwest Nigeria[J].Afr J Med Med Sci, 2012, 41:337-347.
[9] TILLIN T, HUGHES A D, MAYET J, et al.The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans:SABRE (Southall and Brent Revisited)——aprospective population-based study[J].J Am Coll Cardiol, 2013, 61:1777-1786.
[10] 赵水平.高甘油三酯与冠心病风险的相关性[J].中华心血管病杂志, 2011, 39 (9):789-790.
[11] CUSTODIS F, LAUFS U.Hypertricglyceridemia:prognostic impact and treatment options[J].Dtsch Med Wochenschr, 2011, 136:1533-1542.
[12] 杨沛, 段雷波, 陈伟.高甘油三酯血脂与冠心病的关系[J].中国误诊学杂志, 2002, 2 (3):373-374.
[13] ATAR I A, ATAR I, AYDINALP A, et al.Is there any relationship between coronary artery disease and postprandial triglyceride levels?[J].Anadolu Kardiyol Derq, 2011, 11:201-206.
[14] ONAT A, SANSOY V, YILDIRIN B.Which fasting triglyceride levels best reflect coronary risk?Evidence from the Turkish Adult Risk Factor Study[J].Clin Cardiol, 2001, 24:9-14.
[15] 黄秋霞, 姜徳谦.冠心病患者血清甘油三酯水平与纤溶激活系统的关系[J].中国动脉硬化杂志, 2001, 9 (4):316-320.
[16] PUCCETTI L, BRUNI F, PASQUI A L, et al.Dyslipidemias and fibrinolysis[J].Ital Heart J, 2002, 3:579-86.
[17] HOKANSON J E, AUSTIN M A.Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level:a meta-analysis of population-based prospective studies[J].J Cardiovasc Risk, 1996, 3:213-219.
[18] Asia Pacific Cohort Studies Collaboration.Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region[J].Circulation, 2004, 110:2678-2686.
[19] DI ANGELANTONIO E, SARWAR N, PERRY P, et al.Major lipids, apolipoproteins, and risk of vascular disease[J].JAMA, 2009;302:1993-2000.
[20] MILLER M, CANNON C P, MURPHY S A, et al.Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22trial[J].J Am Coll Cardiol, 2008, 51:724-730.
[21] FAERGEMAN O, HOLME I, FAYYAD R, et al.Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease[J].Am J Cardiol, 2009, 104:459-463.
[22] WATTS G F, KARPE F.Triglycerides and atherogenic dyslipidaemia:extending treatment beyond statins in the high-risk cardiovascular patient[J].Heart, 2011, 97:350-356.
[23] ERICSSON C G, HAMSTEN A, NILSSON J, et al.An angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients[J].Lancet, 1996, 347:849-853.
[24] MANNINEN V, TENKANEN L, KOSKINEN P, et al.Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study:implications for treatment[J].Circulation, 1992, 70:733-737.
[25] MOSCA L, BENJAMIN E J, BERRA K, et al.Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011update:aguideline from the American Heart Association[J].Circulation, 2011, 123:1243-1262.
[26] YOKOYAMA M, ORIGASA H, MATSUZAKI M, et al.Japan EPA Lipid Intervention Study (JELIS) Investigators.Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS):a randomised open-label, blinded endpoint analysis[J].Lancet, 2007, 369:1090-1098.
[27] The ACCORD Study Group.Effects of combination lipid therapy in type 2diabetes mellitus[J].N Engl J Med, 2010, 362:1563-1574.
[28] KASAI T, MIYAUCHI K, YANAGISAWA N, et al.Mortality risk of triglyceride levels in patients with coronary artery disease[J].Heart, 2013, 99:22-29.
[29] KANNEL W B, VASAN R S.Triglycerides as vascular risk factors:new epidemiologic insights[J].Curr Opin Cardiol, 2009, 24:345-350.
-
计量
- 文章访问数: 36
- PDF下载数: 20
- 施引文献: 0
下载: